BANK VONTOBEL/CALL/ELI LILLY & CO/380/0.1/21.06.24 | Market Closed - Deutsche Boerse AG 18:50:32 31/05/2024 BST | ||
| 40.18 EUR | -0.86% |
|
| 1 month | +6.98% | ||
| 3 months | +14.38% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 40.18 | -0.86% |
| 30/05/24 | 40.53 | +0.90% |
| 29/05/24 | 40.17 | +3.03% |
| 28/05/24 | 38.99 | -2.74% |
| 27/05/24 | 40.09 | +0.70% |
Delayed Quote Deutsche Boerse AG
Last update May 31, 2024 at 06:50 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VU6BR0 |
| ISIN | DE000VU6BR01 |
| Date issued | 17/04/2023 |
| Strike | 380 $ |
| Maturity | 21/06/2024 (20 Days) |
| Parity | 10 : 1 |
| Emission price | 4.86 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 40.9 € |
|---|---|
| Lowest since issue | 4.71 € |
| Spread | 0.02 € |
| Spread % | 0.05% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
820.3
USD
Average target price
852.5
USD
Spread / Average Target
+3.92%
- Stock Market
- Warrants
- Warrant
